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The multi-system nature of sarcoidosis can make it difficult to ascertain the extent of disease in affected patients, especially 
once disease becomes advanced.  As sarcoidosis may involve any system, determination of this disease during a flare 
versus another coexisting disease causing similar findings is particularly challenging4.  A comparable diagnostic dilemma 
emerges with determining the presence of hemophagocytic lymphohistiocytosis (HLH) as this disease manifests in those with 
pervasive illness1,2.  
A 72 year old male with significant history of sarcoidosis with biopsy-proven bone marrow and prostate involvement as 
well as limited systemic sclerosis (positive centromere antibody with Raynauds, telangiectasias, and puffy hands) admitted 
with fever and pancytopenia.  He was found to have streptococcal mitis/oralis bacteremia of uncertain primary source.  
Empiric prednisone therapy was initiated for pancytopenia along with intravenous (IV) antibiotics for presumed active sarcoid 
involvement of his bone marrow.  The patient’s fevers resolved after addition of high dose steroid therapy.  The patient was 
discharged home on oral steroids and completion of IV antibiotics.  
The patient was readmitted three days after discharge with symptomatic hypercalcemia, recurrent fevers, and persistent 
pancytopenia.  He underwent a bone marrow biopsy which indicated presence of hemophagocytosis, supportive of HLH, 
in the background of mildly hypercellular bone marrow aspirate and features of sarcoid involvement, specifically lobular 
disarray with scattered epithelioid granulomas.  HLH diagnosis was ultimately supported with criteria used in the HLH 2004 
trial by findings of hemophagocytosis on bone marrow biopsy, elevated soluble CD 25 (soluble IL-2 receptor alpha), peripheral 
blood cytopenia, hypofibrinogenemia, and splenomegaly.  He was empirically treated with three doses of Etoposide as well 
as Dexamethasone per HLH treatment protocol.  His pancytopenia failed to improve on the induction therapy and repeat bone 
marrow biopsy was completed.  Second bone marrow biopsy results yielded post-chemotherapy hypo cellular bone marrow 
aspirate with stromal changes, residual sarcoid granulomas, and no evidence of hemophagocytosis.  Due to the incongruence 
of hemophagocytosis resolution without appropriate improvement in the patient’s pancytopenia, the patient was transferred 
to an academic center for further reassessment where review supported extensive sarcoid involvement of the bone marrow 
rather than de-novo HLH.  During this hospitalization, the patient developed progressive hepatic failure and was found to 
have cirrhosis suspected to be related to infiltrative sarcoid process.
CONCLUSION
This case highlights the clinical quandary of determining the true presence of HLH with active sarcoid involvement in the bone 
marrow1.  Upon reflection, factors outside the marrow such as cirrhosis likely played a role in misinterpretation of factors 
that would typically be supportive of HLH diagnosis, such as hypofibrinogenemia, normal triglycerides, and normal ferritin.  
Hemophagocytosis seen on the patient’s bone marrow biopsy demonstrated initially excessive macrophage activation, 
therefore can be supportive of an HLH disease process, however this finding neither is pathognomonic nor needs to be 
present for HLH diagnosis2,3.  Prompt treatment of HLH if highly suspected is imperative given the life-threatening nature of 
the disease1, although treatment of suspected HLH in this case was of no clinical benefit.  Lack of response should and did 
require reevaluation of the initial diagnosis.  Means of early and correct diagnosis of alternative disease processes in cases of 
advanced sarcoidosis is imperative. 
Table 1. HLH Diagnostic Criteria
Features of HLH Presence in our Patient
Fever >38.5 degrees Celsius No
Splenomegaly Yes
Peripheral blood cytopenia (two of the following: Hgb <9, PLT<100K, ANC<1000) Yes
Hypertriglyceridemia (fasting triglycerides>256) and/or hypofibrogenemia (fibrinogen<150) Yes
Hemophagocytosis in bone marrow aspirate, spleen, lymph node, or liver Yes
Ferritin >500 (> 3000 more indicative of HLH) No
Low or absent NK cell activity Uncertain
Elevated soluble CD25 (soluble IL-2 receptor alpha) two standard deviations above age-adjusted normal range Yes
Comment: At least five out of the above eight features should be present for HLH diagnosis based 
on diagnostic criteria used in the HLH 2004 trial for those without molecular identification of an HLH-
associated gene mutation1,2.
Comment: Both photos from initial bone marrow biopsy sample collected 4/24/17 demonstrating 
hemophagocytosis.
Comment: Both of the above photos are bone marrow biopsy aspirates from the second sample 
5/19/17 status post treatment for HLH demonstrating granulomas (no hemophagocytosis identified).
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